1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮
- CAS号:11023-94-2
- 英文名:Nothofagin
- 中文名:1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮
- CBNumber:CB73037431
- 分子式:C21H24O10
- 分子量:436.41
- MOL File:11023-94-2.mol
- 储存条件 :under inert gas (nitrogen or Argon) at 2-8°C
- 形态 :Solid
- 颜色 :White to off-white
1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮性质、用途与生产工艺
- 生物活性 Nothofagin 是一种二氢查尔酮，是从如意宝 (Aspalathus linearis) 中分离得到的。Nothofagin 通过阻断钙 (calcium) 内流来下调 NF-κB 的转运。Nothofagin 具有抗氧化活性，可改善各种炎症反应，例如脓毒症反应和血管炎症。
-
体外研究
Nothofagin pre-treatment (0.1, 1, 10 μM) decreases the level of histamine release in RBL-2H3 and RPMCs cells. The production of cytokines are downregulated bynothofagin pre-treatment Nothofagin (TNF-α: 1-10 μM; IL-4: 0.1-10 μM, IL-6: 1-10 μM).
Pre-treatment of DNPHSA-stimulated RBL-2H3 with Nothofagin (10 μM) markedly suppresses the phosphorylation of Lyn, Syk, and Akt.
Nothofagin (30 μM; for 6 hours) results in inhibited formation of LPS-induced (100 ng/mL; 4 hours) paracellular gaps with the formation of dense F-actin rings in HUVECs.
Nothofagin suppresses IgE-mediated mast cell degranulation both in vitro and in vivo.
-
体内研究
Nothofagin (1 mg/kg; orally; once a day; for 7 days) significantly increases the urinary volume of both normotensive (NTR) and spontaneously hypertensive rats (SHR).
Animal Model: Male Wistar normotensive and spontaneously hypertensive rats (3-4 months old) Dosage: 1 mg/kg Administration: Orally; once a day; for 7 days Result: Significantly increased the urinary volume of both NTR and SHR.
- 更新日期：2025/02/08
- 产品编号：HY-113919
- 产品名称：1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮 Nothofagin
- CAS编号：11023-94-2
- 包装：1 mg
- 价格：5819元
- 更新日期：2023/03/20
- 产品编号：HY-113919
- 产品名称：1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮 Nothofagin
- CAS编号：11023-94-2
- 包装：5mg
- 价格：12500元
- 公司名称：CLEARSYNTH LABS LTD.
- 联系电话：--
- 电子邮件：sales@clearsynth.com
- 国家：印度
- 产品数：6257
- 优势度：58
